Menu
1 min read · estimated
APPROVED USE
What FDA approved
For metastatic basal cell carcinoma after a hedgehog pathway inhibitor or when such an inhibitor is unsuitable.
LAMPGEN ANALYSIS
Why it matters
FDA converted the accelerated metastatic basal cell carcinoma use after confirmatory evidence.
What research teams should watch
Document prior hedgehog inhibitor treatment or the reason it is unsuitable and keep this entry separate from locally advanced disease.
PRIMARY RECORDS